Roche's Elecsys pTau181 test is the second blood-based biomarker test to receive FDA clearance for Alzheimer’s disease this year. Sarah Silbiger/Getty Images

The US Food and Drug Administration has given clearance to another blood test to help assess Alzheimer’s disease and other causes of cognitive decline, providing a broader understanding of when the disease can be ruled out.

Roche Diagnostics said Monday that its Elecsys pTau181 test, developed in collaboration with Eli Lilly, could be used by primary care physicians to help identify patients who are unlikely to have Alzheimer’s disease, while those with a positive result would be recommended for further testing.

The test is intended for adults 55 and older in the United States who are showing signs or symptoms of cognitive dec

See Full Page